Cardiovascular Disease Doctors in Missoula, MT Accepting Medicare

16 Cardiovascular Disease doctors found. Showing 1 - 16

Daniel B Spoon, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St Ste 320, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-2791

Dr. Newton Basil Coutinho, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2419 Mullan Rd Ste A, Missoula, MT 59808 Phone: 406-541-1400    Fax: 406-541-1401

George H. Reed, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Suite 320, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-5606

Bradley D Berry, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St, Suite 320, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-5606

Dr. Michael C Reed, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 West Broadway, St. Patrick Hospital, Missoula, MT 59802 Phone: 406-543-7271

W. Stanley Wilson, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 601 W Spruce St Ste A, Missoula, MT 59802 Phone: 406-329-2945    Fax: 406-329-2938

Philip A. Roper, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 601 W Spruce St Ste A, Missoula, MT 59802 Phone: 406-329-2945    Fax: 406-329-2938

Dr. Jocelyn Nichole Spoon, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St, Suite 320, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-2791

Carolyn C. Goren, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Suite 320, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-5606

Jon Brant Mcgregor, M. D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St Ste 320, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-5606

Mark L. Sanz, MD Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Suite 320, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-5606

Alexander Brockman Jehle, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St, Suite 320, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-2791

Ashley Mays, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 W. Broadway, Missoula, MT 59802 Phone: 406-327-1918    Fax: 406-329-2937

Dr. Matthew Cortright Weiss, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2827 Fort Missoula Rd Bldg 5, Missoula, MT 59804 Phone: 406-327-4646

James T Maddux, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St, Suite 320, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-5606

Dr. Michael Wayne Yerkey, M.D., F.A.C.C. Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-329-5615    Fax: 406-329-2791

News Archive

Novel therapies to prevent metastasis

In a study that could point to novel therapies to prevent cancer spread, or metastasis, researchers at the University of California, San Diego (UCSD) School of Medicine have targeted a sugar that supports blood vessel growth in the tumor.

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

BioTime, Inc., Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration (AMD).

Results of Phase 1 study of Oral AEZS-112 announced by Aeterna Zentaris

Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) ("the Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the completion of a Phase 1 study of its orally-active tubulin and topoisomerase II inhibitor compound, AEZS-112, in patients with advanced solid tumors or lymphoma, which may potentially provide a new therapeutic approach for the treatment of cancer.

Environmental pollutants found to worsen rheumatoid arthritis

Scientists have uncovered a link between the risk of developing rheumatoid arthritis and environmental pollutants, such as cigarette smoke.

GAO: Most insurers met health law spending rules - even before they kicked in

Most U.S. health insurers last year would have satisfied the much-disputed spending rules under President Barack Obama's healthcare reform, according to a new report by a congressional watchdog agency... In a report posted online on Wednesday, the Government Accountability Office looked at the insurance plans in 2010, before the new rules took effect, and found that at least 64 percent of eligible insurers would comply with the spending rates.

Read more Medical News

› Verified 8 days ago